RxDoctor Payments Data

Jennifer Olsen

Psychiatric/Mental Health · Sandy, UTNPI 1801413943

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 25.9% of the total. Among psychiatric/mental health clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,197in general payments, 2019–2025

Across 311 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$522
  • Neurocrine Biosciences, Inc.$520
  • Supernus Pharmaceuticals, Inc.$492
  • Teva Pharmaceuticals USA, Inc.$385
  • Lundbeck LLC$328
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,197100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,197 in reported general payments places this provider in the 95th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl15$22,978
Duloxetine Hcl12$1,109
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine28$343
Gabapentin23$316
Bupropion Hcl SrBupropion Hcl13$181
Topiramate12$150
Quetiapine Fumarate13$104
Trazodone Hcl14$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,603$22,97815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 psychiatric/mental health providers in Utah.

Other psychiatric/mental health in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →